T
Thomas Martin
Researcher at University of California, San Francisco
Publications - 311
Citations - 17918
Thomas Martin is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Medicine & Exocytosis. The author has an hindex of 73, co-authored 242 publications receiving 15771 citations. Previous affiliations of Thomas Martin include Institut national de la recherche agronomique & University of Western Australia.
Papers
More filters
Journal ArticleDOI
Docked Secretory Vesicles Undergo Ca2+-activated Exocytosis in a Cell-free System
TL;DR: A cell-free system for Ca2+-activated fusion will facilitate studies on the roles of essential proteins such as syntaxin, synaptobrevin, SNAP-25, and CAPS that act at post-docking steps in the regulated exocytotic pathway.
Journal ArticleDOI
Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma.
Thomas Martin,Stephen A. Strickland,Martha Glenn,Eric Charpentier,Hélène Guillemin,Karl Hsu,Joseph Mikhael +6 more
TL;DR: Isatuximab demonstrated a manageable safety profile and clinical activity in patients with RRMM and the maximum tolerated dose (MTD) was not reached; no cumulative adverse reactions were noted.
Journal ArticleDOI
Role of phosphoinositide signaling in the control of insulin exocytosis.
TL;DR: The data indicate that the production of PI(4,5)P(2) is necessary for proper control of beta-cell secretion and suggest that at least part of the effect of PI on insulin exocytosis could be exerted through the activation of phospholipase D1, Ca(2+)-dependent activator protein for secretion 1, and Munc18-interacting protein 1.
Journal ArticleDOI
The molecular machinery for fast and slow neurosecretion
TL;DR: Regulated peptide secretion from dense-core granules has been found to utilize a similar machinery for docking/fusion, and recent studies indicate that this pathway involves a pre-docking step that is regulated by a higher affinity Ca2+ sensor.
Journal ArticleDOI
Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104
Philip L. McCarthy,Kouros Owzar,Kenneth C. Anderson,Craig C. Hofmeister,David D. Hurd,Hani Hassoun,Sergio Giralt,Edward A. Stadtmauer,Paul G. Richardson,Daniel J. Weisdorf,Ravi Vij,Jan S. Moreb,Natalie S. Callander,Koen van Besien,Teresa C. Gentile,Luis Isola,Richard T. Maziarz,Don A. Gabriel,Asad Bashey,Heather Landau,Thomas Martin,Muzaffar H. Qazilbash,Denise Levitan,Brian McClune,Vera Hars,John Postiglione,Chen Jiang,Elizabeth Bennett,Susan Barry,Linda Bressler,Michael Kelly,Michele Sexton,Cara A. Rosenbaum,Hari Parameswaran,Marcelo C. Pasquini,Mary M. Horowitz,Thomas C. Shea,Steven M. Devine,Charles A. Linker +38 more
TL;DR: This updated 3rd interim analysis for TTP includes further events up until 12/17/09 after which study pts were un-blinded and there is no difference between these two arms.